CLINICAL NEWS
Trial Roundup
ASH Clinical News’ Associate Editors select
clinical trials to keep an eye on.
LEUKEMIA
David Steensma, MD
Dana-Farber Cancer Institute
A Study of the Safety and Pharmacokinetics of RO6839921, an MDM2 Antagonist,
in Patients with Advanced Cancers, including
Acute Myeloid Leukemia (NCT02098967)
study design:
Non-randomized, open-label, parallelassignment safety study
study start date: April 2014
estimated study completion date: September 2015
study status: Currently recruiting participants
estimated enrollment: 90
sponsor: Hoffman-La Roche
While the tumor suppressor p53 is an attractive cancer target (since it is inactivated in many neoplasms, including a
subset of AML), thus far no therapy effectively targets p53.
One mechanism of p53 inactivation is suppression by the
MDM2 protein. Small molecules that block the interaction
of MDM2 with p53 can reactivate the p53 function and may
be a useful strategy for the treatment of cancers retaining
wild-type p53. This approach is not expected to be active if
p53 itself is genetically altered (i.e., mutated or deleted).
use, or how to best prevent venous thromboembolism
(VTE). Here is a selection of trials investigating these
questions.
LYMPHOMA & MYELOMA
Reduced-Dosed Rivaroxaban in the
Long-Term Prevention of Recurrent
Symptomatic VTE (NCT02064439)
A Phase 1-2 Multi-Center Study Evaluating
KTE-C19 in Subjects With Refractory )